Ovarian Cancer

Premal Thaker, MD, MS, highlights data seen with the IL-12 Immunotherapy IMNN-001 in the OVATION-2 trial and next steps with the agent in ovarian cancer.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Premal Thaker, MD, MS, discusses considerations when targeting IL-12 in ovarian cancer and how IMNN-001 has shown the potential to do so.

Whitney Goldsberry, MD, discusses patient characteristics and disease factors that sway the decision between available PARP inhibitors in ovarian cancer.

The European Commission has approved mirvetuximab soravtansine for select patients with pretreated FRα-positive, platinum-resistant ovarian cancer.

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

Sacituzumab tirumotecan monotherapy demonstrated antitumor activity with a manageable safety profile in previously treated endometrial and ovarian cancers.

NXP800 generated antitumor activity as monotherapy in platinum-resistant ovarian cancer harboring ARID1a mutations.

Kathleen N. Moore, MD, MS, discusses the evolving treatment landscape of platinum-resistant ovarian cancer.

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

SHR-A1921 showcased early efficacy with a manageable safety profile in patients with platinum-resistant ovarian cancer.

A rolling NDA seeking the approval of avutometinib plus defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer has been submitted to the FDA.

Laura J. Chambers, DO, discusses the roles of niraparib and olaparib in ovarian cancer and the importance of patient communication throughout treatment.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

Updated RAMP 201 data will support an NDA submission to the FDA for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

Gotistobart plus pembrolizumab demonstrated antitumor activity and a manageable safety profile in platinum-resistant ovarian cancer.

The KIF18A inhibitor VLS-1488 has received fast track designation from the FDA for platinum-resistant high-grade serous ovarian cancer.

Angeles Secord, MD, MHSc, discusses data with mirvetuximab soravtansine in heavily pretreated FRα-positive recurrent, platinum-sensitive ovarian cancer.

Domenica Lorusso, MD, PhD, discusses the rationale for investigating relacorilant combined with nab-paclitaxel in recurrent, platinum-resistant ovarian cancer.

Laura J. Chambers, DO, discusses challenges patients with ovarian cancer face in accessing PARP inhibitor treatment.

The EMA’s CHMP has recommended the marketing authorization of mirvetuximab soravtansine for FRα-positive, platinum-resistant epithelial ovarian cancer.

Angeles A. Secord, MD, MHSc, discusses safety findings from the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive ovarian cancer.

Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

The FDA has lifted the partial clinical hold previously placed on studies evaluating azenosertib in advanced solid tumors.

TORL-1-23 was safe and active in heavily pretreated, Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer.

Angeles A. Secord, MD, MHSc, discusses the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive, FRα-high ovarian cancer.

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

Kimberly Cannavale, MPH, discusses the clinical implications of a study on the impact of pre-existing comorbidities on remission rates in ovarian cancer.

Kimberly Cannavale, MPH, discusses the rationale for investigating the effect of pre-existing comorbidities on remission rates in ovarian cancer.